UPC_CFI_698/2024

METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

Procedural & sub-applicationsDocument Access (RoP262)Milan CDGenericCase Closed

2025-02-03DismissedproceduralApplication RoP262.1 (b)
Application by STADAPHARM GmbH for public access to case documents under R.262.1(b) RoP in the proceedings before the Milan Central Division was dismissed. The court found that STADAPHARM's primary purpose was to expose Novartis's defence strategy in order to facilitate a parallel national (Munich OLG) proceeding rather than to exercise legitimate public oversight. Access was denied as it would create undue pressure on Novartis and undermine the integrity of the proceedings. NOVARTIS's request for costs was also dismissed.